Plasma zaps HPV: new hope for cervical infections?
NCT ID NCT06291311
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether a non-invasive physical plasma treatment can clear HPV infections from the cervix. About 50 adults with HPV will receive the treatment, and researchers will check if the virus is gone afterward. The goal is to find a new way to prevent cervical cancer caused by HPV.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study includes patients aged 18 and over from the dysplasia clinic of the University Women's Hospital Tübingen who have been diagnosed with an infection of the cervix uteri involving both high- and low-risk HPV viruses.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inclusion criteria for NIPP treatment * Age ≥ 18 years * mRNA or DNA-based virus detection by smear (also external findings) * Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2 * Written informed consent to participate in the study * Inclusion criteria for control group * Age ≥ 18 years * Swab-based mRNA or DNA-based virus detection (also external findings) * Clearly visible transformation zone of the cervix corresponding to T1/T2 * Written informed consent to participate in the study Exclusion criteria: The following exclusion criteria apply to both groups of patients (NIPP treatment and control group). * Transformation zone not fully visible * Evidence of invasive disease * Serious cardiovascular diseases
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital Tuebingen, Department of Women's Health
RECRUITINGTübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsed radiation extend life in metastatic cervical cancer?
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Smart speculum could bring cervical cancer screening to remote areas
- Your gut bacteria may hold the key to whether immunotherapy works
- Amazon plant put to the test against Cancer's relentless tiredness